Physician profile
Ryan Pyles
NPI 1003371410
$6,651.97
in general payments reported to CMS, 2019-2025
37 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,355 · 2022: $728 · 2023: $1,942 · 2024: $1,379 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,569.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,280.26 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $954.65 | 2021 | |
| Novo Nordisk INC | $951.03 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $723.45 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $534.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $289.37 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Ibsa Pharma INC. | $188.88 | 2022-2025 | Tirosint, Licart, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.99 | 2022-2024 | Jardiance |
| Amgen INC. | $177.51 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $143.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $107.61 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $95.19 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $77.37 | 2021-2023 | Xarelto |
| Astellas Pharma US INC | $75.15 | 2022-2024 | Veozah |
| Tolmar, INC. | $74.67 | 2023-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Pyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.